

HALOZYME THERAPEUTICS INC  
Form 8-K  
July 03, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**July 3, 2013**

**HALOZYME THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**001-32335**  
(Commission

File Number)

**88-0488686**  
(IRS Employer

Identification No.)

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

**11388 Sorrento Valley Road, San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 794-8889**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

Attached hereto as Exhibit 99.1, which is incorporated herein by reference, is a copy of the slides which formed the basis of Dr. Francisco Perez's presentation to the 9th Annual World Congress of Cosmetic Dermatology on June 29, 2013 in Athens, Greece. Halozyme Therapeutics, Inc. may use some or all of these slides, or the information contained in the slides, in subsequent presentations to interested parties, including analysts and stockholders.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Gynoid Lipodystrophy (Cellulite) (Preliminary Interim Results) Presentation by Dr. Perez-Atamoros.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

July 3, 2013

By: /s/ Jean Liu  
**Jean Liu**  
**Vice President, General Counsel**